- Home
- KRON vs TPST Comparison
KRON vs TPST Comparison
Compare KRON & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- TPST
- Stock Information
- Founded
- KRON 2017
- TPST 2011
- Country
- KRON United States
- TPST United States
- Employees
- KRON N/A
- TPST N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- KRON Health Care
- TPST Health Care
- Exchange
- KRON Nasdaq
- TPST Nasdaq
- Market Cap
- KRON 66.7M
- TPST 36.3M
- IPO Year
- KRON 2020
- TPST N/A
- Fundamental
- Price
- KRON $0.98
- TPST $1.24
- Analyst Decision
- KRON Strong Buy
- TPST Strong Buy
- Analyst Count
- KRON 2
- TPST 4
- Target Price
- KRON $4.13
- TPST $20.75
- AVG Volume (30 Days)
- KRON 119.4K
- TPST 6.5M
- Earning Date
- KRON 08-08-2024
- TPST 11-06-2024
- Dividend Yield
- KRON N/A
- TPST N/A
- EPS Growth
- KRON N/A
- TPST N/A
- EPS
- KRON N/A
- TPST N/A
- Revenue
- KRON $8,412,000.00
- TPST N/A
- Revenue This Year
- KRON $52.62
- TPST N/A
- Revenue Next Year
- KRON N/A
- TPST N/A
- P/E Ratio
- KRON N/A
- TPST N/A
- Revenue Growth
- KRON 172.76
- TPST N/A
- 52 Week Low
- KRON $0.69
- TPST $0.17
- 52 Week High
- KRON $1.60
- TPST $9.77
- Technical
- Relative Strength Index (RSI)
- KRON 39.51
- TPST 38.32
- Support Level
- KRON $0.96
- TPST $1.12
- Resistance Level
- KRON $1.01
- TPST $1.44
- Average True Range (ATR)
- KRON 0.04
- TPST 0.10
- MACD
- KRON 0.01
- TPST 0.01
- Stochastic Oscillator
- KRON 20.42
- TPST 30.00
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.